Boceprevir (Victrelis®)

Assessment Status NCPE Assessment Process Complete
HTA ID -
Drug Boceprevir
Brand Victrelis®
Indication As add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1.
Assessment Process
Full submission received from Applicant 19/08/2011
NCPE assessment completed 17/01/2012
NCPE assessment outcome Reimbursement Recommended

We consider boceprevir a highly cost-effective therapy when added to peginterferon-ribavirin for the treatment of patients infected with genotype 1 hepatitis C virus in the Irish healthcare setting.

Technical Summary